Ocular Therapeutix, Inc.
OCUL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $64 | $58 | $51 | $44 |
| % Growth | 9% | 13.5% | 18.3% | – |
| Cost of Goods Sold | $6 | $5 | $5 | $4 |
| Gross Profit | $58 | $53 | $47 | $39 |
| % Margin | 91.2% | 91% | 91.2% | 89.9% |
| R&D Expenses | $128 | $61 | $53 | $50 |
| G&A Expenses | $61 | $34 | $68 | $32 |
| SG&A Expenses | $102 | $74 | $72 | $67 |
| Sales & Mktg Exp. | $42 | $41 | $4 | $35 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $230 | $136 | $126 | $117 |
| Operating Income | -$172 | -$82 | -$79 | -$78 |
| % Margin | -269.6% | -141% | -152.7% | -179.3% |
| Other Income/Exp. Net | -$22 | $2 | $8 | $71 |
| Pre-Tax Income | -$194 | -$81 | -$71 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$194 | -$81 | -$71 | -$7 |
| % Margin | -303.7% | -138.1% | -138% | -15.1% |
| EPS | -1.22 | -1.09 | -1.04 | -1.05 |
| % Growth | -11.9% | -4.8% | 1% | – |
| EPS Diluted | -1.22 | -1.02 | -0.97 | -0.98 |
| Weighted Avg Shares Out | 158 | 80 | 77 | 76 |
| Weighted Avg Shares Out Dil | 158 | 86 | 83 | 82 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $4 | $1 | $0 |
| Interest Expense | $14 | $11 | $7 | $7 |
| Depreciation & Amortization | $4 | $3 | $2 | $2 |
| EBITDA | -$176 | -$66 | -$62 | $3 |
| % Margin | -276.4% | -113.6% | -120.2% | 5.8% |